Issued by: Centers for Medicare & Medicaid Services (CMS)

Issue Date: January 30, 2020

The Percutaneous Transluminal Angioplasty (PTA) National Coverage Determination (NCD) covers carotid artery stenting (CAS) procedures under certain circumstances including through study participation.  Listed below are the investigational studies covered under sections B2 and B3 of this NCD.

Note: Effective 10/11/2023, section B4 of NCD 20.7 covers a broader patient population, some of which may continue to be involved in investigational studies. When CAS procedures are performed as part of an investigational study under section B2 or B3, the study protocol must be followed. 

 

Registry Approvals

CREST-2 Registry (C2R)
Clinicaltrials.gov number:  NCT02240862
http://clinicaltrials.gov/ct2/show/NCT02240862?term=C2R&rank=1
CMS Approval Date:  09/17/2014

 

Clinical Study Approvals

 

Study Title: The ROADSTER 3 Study
Sponsor:  Silk Road Medical
Clinicaltrials.gov number:  NCT05365490
Premarket Approval (PMA) number:  P140026
CMS Approval Date:  04/28/2022

Study Title: SVS VQI TransCarotid Revascularization Surveillance Project (VQI-TCAR)
Sponsor: Society for Vascular Surgery
Clinicaltrials.gov number: NCT02850588
CMS Approval Date: 09/01/2016

Study Title: ROADSTER 2 Registry
Sponsor:  Silk Road Medical
Clinicaltrials.gov number:  NCT02536378
Premarket Approval (PMA) number:  P140026
CMS Approval Date:  08/03/2015

Study Title:  Carotid Revascularization for Primary Prevention of Stroke (CREST-2)
Sponsor:  National Institute of Neurological Disorders and Stroke (NINDS)
Clinicaltrials.gov number:  NCT02089217
Investigational Device Exemption (IDE) number:  G130221
CMS Approval Date:  09/17/2014

HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.